Clinical TrialJun 1, 2026, 07:01 AM
Jade Biosciences JADE101 Phase 1 shows >70% IgA reduction in IgAN
AI Summary
Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, a novel anti-APRIL monoclonal antibody for IgA nephropathy (IgAN). The trial demonstrated approximately 70% IgA reductions sustained at 12 weeks, with projections for similar reductions at steady-state with quarterly dosing. JADE101 showed a faster, deeper, and more durable IgA-lowering effect and superior potency compared to other agents, alongside a favorable safety profile. The company has advanced JADE101 into a Phase 2 trial and plans to initiate a Phase 3 registrational trial in the first half of 2027.
Key Highlights
- JADE101 Phase 1 trial showed mean IgA reductions of approximately 70% sustained at 12 weeks at the 700 mg dose.
- Greater than 70% IgA reductions projected at steady-state with a single subcutaneous injection of 350 mg every 12 weeks.
- IgA-lowering effect was faster, deeper, and more durable than first-generation anti-APRIL or dual APRIL/BAFF agents.
- JADE101 demonstrated approximately 379-fold higher IgA-lowering potency than sibeprenlimab and 26-fold higher than povetacicept.
- JADE101 was well-tolerated across all evaluated doses up to 1,400 mg, with no serious adverse events.
- Phase 2 clinical trial (JUNIPER) in IgAN patients is underway, with interim clinical data expected in 2027.
- Phase 3 registrational trial is expected to be initiated in the first half of 2027.
Price Impact
More from JBIO